多发性骨髓瘤肾损害患者的临床特征分析
|
摘要
<正>多发性骨髓瘤(multiple myeloma,MM)是血液系统中第二大肿瘤性疾病,恶性浆细胞克隆性分泌免疫球蛋白(M蛋白),引起全身多系统器官的病变,而肾功能损害是其中较常见且严重的并发症[1]。国外研究显示,MM患者肾功能不全发生率可达25%～75%[2],20%～40%的MM患者在确诊时就已合并肾功能损害,且近年来发病率有逐渐上升的趋势。部分MM患者会因乏力、恶心、浮肿等症状直接前往肾内科就诊,被诊断为肾脏疾病。但MM肾脏损伤与非
引文
[1] 朱婉秋,陈文明.IMWG多发性骨髓瘤诊断标准解读[J].临床血液学杂志,2017,30(7):507-509.
[2] Stompór T,Zablocki M,Pankrac K.Renal involvement in multiple myeloma[J].Pol Arch Med Wewn,2012,122:443-448.
[3] 中国医师协会血液科医师分会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):866-870.
[4] Chen JH,Hsu SN,Huang TC,et al.Prognostic significance of initial serum albumin and 24 hour daily protein excretion before treatment in multiple myeloma[J].PLoS One,2015,10:e0128905.
[5] 唐江涛,李立新,冯伟华,等.免疫固定电泳和血轻链比值诊断以肾脏损伤为首发症状的多发性骨髓瘤的价值[J].四川大学学报(医学版),2016,47(4):551-555.
[6] Almueilo SH.Renal failure in patients with multiple myeloma[J].Saudi J Kidney Dis Transpl,2015,26:482-488.
[7] 钟赟,侯健.多发性骨髓瘤肾损害早期评估的研究进展[J].临床血液学杂志,2012,25(7):418-420.
[8] Eleftherakis-Papapiakovou E,Kastritis E,Roussou M,et al.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens[J].Leuk Lymphoma,2011,52:2299-2303.
[9] 刘诗静.多发性骨髓瘤合并早期肾脏损害的临床分析[D].广州:南方医科大学,2013.
[10] Neri LAL,Mendes ME,David Neto-E,et al.Cystatin C measurement as renal function marker[J].J Bras Patol Med Lab,2010,46:443-453.
[11] Nückel H,Langer C,Herget-Rosenthal S,et al.Prognostic significance of serum cystatin C in multiple myeloma[J].Int J Hematol,2012,95:545-550.
[12] 苏显都,林榕,徐晓兰,等.血清胱抑素C、β2-微球蛋白及肌酐在多发性骨髓瘤诊断中的价值[J].解放军医学院学报,2014,35(11):1126-1129.
[13] 袁新科,黄映红,李萌,等.尿NGAL与Cys-C用于诊断多发性骨髓瘤早期肾损伤的临床价值研究[J].肿瘤药学,2016,6(2):142-145.
[14] 吕亚莉.血沉在多发性骨髓瘤肾病诊断中的价值[J].现代实用医学,2010,22(3):324-325.
[15] 孙立娜.多发性骨髓瘤肾病的相关检验分析[D].北京:首都医科大学,2013.
[16] 刘艳,王贞,李艳莲,等.10例轻链型多发性骨髓瘤的实验室结果分析[J].中国实验诊断学,2012,16(2):245-248.
[2] Stompór T,Zablocki M,Pankrac K.Renal involvement in multiple myeloma[J].Pol Arch Med Wewn,2012,122:443-448.
[3] 中国医师协会血液科医师分会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):866-870.
[4] Chen JH,Hsu SN,Huang TC,et al.Prognostic significance of initial serum albumin and 24 hour daily protein excretion before treatment in multiple myeloma[J].PLoS One,2015,10:e0128905.
[5] 唐江涛,李立新,冯伟华,等.免疫固定电泳和血轻链比值诊断以肾脏损伤为首发症状的多发性骨髓瘤的价值[J].四川大学学报(医学版),2016,47(4):551-555.
[6] Almueilo SH.Renal failure in patients with multiple myeloma[J].Saudi J Kidney Dis Transpl,2015,26:482-488.
[7] 钟赟,侯健.多发性骨髓瘤肾损害早期评估的研究进展[J].临床血液学杂志,2012,25(7):418-420.
[8] Eleftherakis-Papapiakovou E,Kastritis E,Roussou M,et al.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens[J].Leuk Lymphoma,2011,52:2299-2303.
[9] 刘诗静.多发性骨髓瘤合并早期肾脏损害的临床分析[D].广州:南方医科大学,2013.
[10] Neri LAL,Mendes ME,David Neto-E,et al.Cystatin C measurement as renal function marker[J].J Bras Patol Med Lab,2010,46:443-453.
[11] Nückel H,Langer C,Herget-Rosenthal S,et al.Prognostic significance of serum cystatin C in multiple myeloma[J].Int J Hematol,2012,95:545-550.
[12] 苏显都,林榕,徐晓兰,等.血清胱抑素C、β2-微球蛋白及肌酐在多发性骨髓瘤诊断中的价值[J].解放军医学院学报,2014,35(11):1126-1129.
[13] 袁新科,黄映红,李萌,等.尿NGAL与Cys-C用于诊断多发性骨髓瘤早期肾损伤的临床价值研究[J].肿瘤药学,2016,6(2):142-145.
[14] 吕亚莉.血沉在多发性骨髓瘤肾病诊断中的价值[J].现代实用医学,2010,22(3):324-325.
[15] 孙立娜.多发性骨髓瘤肾病的相关检验分析[D].北京:首都医科大学,2013.
[16] 刘艳,王贞,李艳莲,等.10例轻链型多发性骨髓瘤的实验室结果分析[J].中国实验诊断学,2012,16(2):245-248.